Mallinckrodt’s spending on political donations and lobbying comes as the drug industry as a whole beefs up its Capitol Hill presence.
NYS Entity Status
NYS Filing Date
JUNE 26, 2013
NYS DOS ID#
NYS Entity Type
DOMESTIC BUSINESS CORPORATION
2013 - GRYPHON PHARMACEUTICAL LOGISTICS INC
Around the Web
- A Drug Maker Spends Big in Washington to Make Itself Heard
By JAY HANCOCK, ELIZABETH LUCAS and SYDNEY LUPKIN - Friday Jul 21, 2017
- Impax Laboratories and Amneal Pharmaceuticals Near Merger Agreement
Monday Oct 16, 2017
Impax Laboratories Inc. and Amneal Pharmaceuticals LLC are close to agreement on a merger that would create the nation’s fifth-largest generic-drug company by revenue, according to people familiar with the matter.
- Stealthy NY Startup Rocket Pharma Merges With Inotek, Heads to Nasdaq
By Ben Fidler - Tuesday Sep 12, 2017
Rocket Pharmaceuticals, a stealthy gene therapy startup in New York City, has made its first splash. Through a merger with struggling Inotek Pharmaceuticals (NASDAQ: ITEK), Rocket, a company developing treatments for a variety of rare blood diseases, has taken itself public. Rocket shareholders are expected to own 81 percent of the combined company, with Inotek […]
- Raiders DT Darius Latham suspended for 4 games
By Ron Kroichick - Monday Oct 9, 2017
Raiders defensive tackle Darius Latham was suspended for four games without pay for violating the NFL’s substance abuse policy, the league announced Monday. Latham will be eligible to rejoin the team Nov. 6, the day after Oakland’s game in Miami against the Dolphins. Latham, 22, is a second-year player from Indiana. He played in 14 games last season for the Raiders (with 17 tackles), and he had played in one of the team’s five games this season — Sunday’s 30-17 loss to Baltimore at the Coliseum. Latham assisted on two tackles. Ron Kroichick is a San Francisco Chronicle staff writer. Email: rkroichick@sfchronicle.
- Considering the Side Effects of Drugmakers’ Money-Back Guarantees
By KATIE THOMAS and CHARLES ORNSTEIN - Monday Jul 10, 2017
The Trump administration is considering encouraging lowering drug costs through outcome-based contracts, but there is little evidence the approach works.